October 8, 2009
ULM professor publishes an article in online peer-reviewed journal
Professor Yong-Yu Liu's previous research shows that the drug-resistant gene, glucosylceramide synthase (GCS), is a potential candidate for cancer chemotherapy.
His study published in PLoS One reports that a novel way has been found to reverse the gene's drug resistance, using a new mixed-backbone oligonucleotide, identified as MBO-asGCS. This new DNA-RNA oligonucleotide specifically disrupts the GCS "bad" gene and kills more cancer cells.
"This work is very important for understanding the mystery of cancer drug resistance," said Liu. "And MBO-asGCS is a highly promising agent. It might substantially reduce chemotherapy failure and the side-effects of chemotherapy."
More than 500,000 Americans die every year from cancer, due to the failure of chemotherapy treatments. A cancer cell's drug resistance is the result of gene alteration and represents the biological basis for the chemotherapy failures, said Liu.